id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2010-N-0381-0057,FDA,FDA-2010-N-0381,"Nostrum Pharmaceuticals, LLC - Letter",Other,Letter(s),2012-09-23T04:00:00Z,2012,9,2012-09-23T04:00:00Z,,2012-09-23T16:07:18Z,,0,0,0900006480fdb963
FDA-2010-N-0381-0051,FDA,FDA-2010-N-0381,Meetings: Generic Drug User Fee; Correction,Notice,General Notice,2011-12-21T05:00:00Z,2011,12,2011-12-21T05:00:00Z,,2011-12-21T22:13:01Z,2011-32562,0,0,0900006480f870d0
FDA-2010-N-0381-0048,FDA,FDA-2010-N-0381,Generic Drug User Fee; Public Meeting,Notice,Meeting,2011-12-08T05:00:00Z,2011,12,2011-12-08T05:00:00Z,2012-01-07T04:59:59Z,2011-12-08T14:13:25Z,2011-31630,0,0,0900006480f7df83
FDA-2010-N-0381-0046,FDA,FDA-2010-N-0381,Generic Drug User Fee; Request for Comments,Notice,Meeting,2011-07-22T04:00:00Z,2011,7,2011-07-22T04:00:00Z,2011-09-27T03:59:59Z,2011-07-22T15:06:10Z,2011-18591,0,0,0900006480ec9599
FDA-2010-N-0381-0042,FDA,FDA-2010-N-0381,Generic Drug User Fee; Extension of Comment Period,Notice,NEC-Notice of Extension,2011-06-08T04:00:00Z,2011,6,2011-06-08T04:00:00Z,2011-08-02T03:59:59Z,2011-06-08T16:37:43Z,2011-14120,0,0,0900006480e40148
FDA-2010-N-0381-0041,FDA,FDA-2010-N-0381,Generic Drug User Fee; Public Meeting; Request for Comments,Notice,N-Notice,2011-04-29T04:00:00Z,2011,4,2011-04-29T04:00:00Z,2011-06-11T03:59:59Z,2011-04-29T14:05:42Z,2011-10382,0,0,0900006480c3bf40
FDA-2010-N-0381-0038,FDA,FDA-2010-N-0381,Generic Drug User Fee; Notice of Public Meeting; Reopening of the Comment Period,Notice,NEC-Notice of Extension,2011-03-15T04:00:00Z,2011,3,2011-03-15T04:00:00Z,2011-07-01T03:59:59Z,2011-03-18T19:48:31Z,2011-05917,0,0,0900006480c07f7e
FDA-2010-N-0381-0035,FDA,FDA-2010-N-0381,Generic Drug User Fee; Notice of Public Meeting; Reopening of the Comment Period,Notice,N-Notice,2011-01-24T05:00:00Z,2011,1,2011-01-24T05:00:00Z,2011-02-24T04:59:59Z,2011-02-18T18:59:02Z,2011-01274,0,0,0900006480bd126e
FDA-2010-N-0381-0031,FDA,FDA-2010-N-0381,Generic Drug User Fee; Notice of Public Meeting; Reopening of the Comment Period,Notice,NEC-Notice of Extension,2010-11-04T04:00:00Z,2010,11,2010-11-04T04:00:00Z,2010-12-07T04:59:59Z,2010-11-22T19:01:39Z,2010-27824,0,0,0900006480b80cae
FDA-2010-N-0381-0029,FDA,FDA-2010-N-0381,See FDA-2010-N-0381-0032,Supporting & Related Material,,2010-11-03T00:00:00Z,2010,11,,,2012-03-24T19:34:22Z,,0,1,0900006480b70f32
FDA-2010-N-0381-0030,FDA,FDA-2010-N-0381,See FDA-2010-N-0381-0032,Supporting & Related Material,,2010-11-03T00:00:00Z,2010,11,,,2012-03-24T19:34:29Z,,0,1,0900006480b71758
FDA-2010-N-0381-0007,FDA,FDA-2010-N-0381,"Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research (CDER), Generic Drug User Fee; Public Meeting, September 17, 2010 - Presentation",Other,TS-Testimony,2010-10-07T04:00:00Z,2010,10,2010-10-07T04:00:00Z,,2013-07-27T23:34:04Z,,0,0,0900006480b6a6d4
FDA-2010-N-0381-0009,FDA,FDA-2010-N-0381,"Brian J. Hasselbalch, Team Leader, Division of Manufacturing and Product Quality, Office of Compliance, CDER, Generic Drug User Fee; Public Meeting, September 17, 2010 - Presentation",Other,TS-Testimony,2010-10-07T04:00:00Z,2010,10,2010-10-07T04:00:00Z,,2013-07-27T23:34:05Z,,0,0,0900006480b6a6d6
FDA-2010-N-0381-0011,FDA,FDA-2010-N-0381,"Jonah Houts, Alliance for Affordable Medicine, Generic Drug User Fee; Public Meeting, September 17, 2010 - Presentation",Other,TS-Testimony,2010-10-07T04:00:00Z,2010,10,2010-10-07T04:00:00Z,,2013-07-27T23:34:05Z,,0,0,0900006480b6a6d8
FDA-2010-N-0381-0013,FDA,FDA-2010-N-0381,"Ahaviah Diane Glaser, American Association of Retired Persons (AARP), Generic Drug User Fee; Public Meeting, September 17, 2010 - Presentation",Other,TS-Testimony,2010-10-07T04:00:00Z,2010,10,2010-10-07T04:00:00Z,,2013-07-27T23:34:05Z,,0,0,0900006480b6a6da
FDA-2010-N-0381-0015,FDA,FDA-2010-N-0381,"William Vaughan, Consumers Union, Generic Drug User Fee; Public Meeting, September 17, 2010 - Presentation",Other,TS-Testimony,2010-10-07T04:00:00Z,2010,10,2010-10-07T04:00:00Z,,2013-08-11T01:37:28Z,,0,0,0900006480b6a731
FDA-2010-N-0381-0005,FDA,FDA-2010-N-0381,"Generic Drug User Fee Act (GDUFA) Attendee Meeting List, September 17, 2010 - List",Other,LST-List,2010-10-07T04:00:00Z,2010,10,2010-10-07T04:00:00Z,,2013-07-27T23:34:04Z,,0,0,0900006480b6a6d2
FDA-2010-N-0381-0018,FDA,FDA-2010-N-0381,"K.L. Spear M.D., Spear Pharmaceuticals, Generic Drug User Fee; Public Meeting, September 17, 2010 - Presentation",Other,TS-Testimony,2010-10-07T04:00:00Z,2010,10,2010-10-07T04:00:00Z,,2013-07-27T23:34:06Z,,0,0,0900006480b6a736
FDA-2010-N-0381-0016,FDA,FDA-2010-N-0381,"Paul Brown, National Research Center(NRC) for Women and Families, Generic Drug User Fee; Public Meeting, September 17, 2010 - Presentation",Other,TS-Testimony,2010-10-07T04:00:00Z,2010,10,2010-10-07T04:00:00Z,,2013-07-27T23:34:05Z,,0,0,0900006480b6a732
FDA-2010-N-0381-0019,FDA,FDA-2010-N-0381,"Richard J. Stec, Jr., Generic Drug User Fee Coalition Members (Apotex Corp.,Hospira Inc.,Perrigo Company, and Teva Pharmaceuticals USA), Generic Drug User Fee; Public Meeting, September 17, 2010 - Presentation",Other,TS-Testimony,2010-10-07T04:00:00Z,2010,10,2010-10-07T04:00:00Z,,2013-07-27T23:34:05Z,,0,0,0900006480b6a734
FDA-2010-N-0381-0021,FDA,FDA-2010-N-0381,"Generic Drug User Fee; Public Meeting, September 17, 2010 - Transcript",Other,TR-Transcript,2010-10-07T04:00:00Z,2010,10,2010-10-07T04:00:00Z,,2013-07-27T23:34:06Z,,0,0,0900006480b6a737
FDA-2010-N-0381-0017,FDA,FDA-2010-N-0381,"Gordon Johnston, Generic Pharmaceutical Association (GPhA), Generic Drug User Fee; Public Meeting, September 17, 2010 - Presentation",Other,TS-Testimony,2010-10-07T04:00:00Z,2010,10,2010-10-07T04:00:00Z,,2013-07-27T23:34:05Z,,0,0,0900006480b6a733
FDA-2010-N-0381-0014,FDA,FDA-2010-N-0381,"Kasey Thompson, American Society of Health-Systems Pharmacy (ASHP), Generic Drug User Fee; Public Meeting, September 17, 2010 - Presentation",Other,TS-Testimony,2010-10-07T04:00:00Z,2010,10,2010-10-07T04:00:00Z,,2013-08-11T03:11:10Z,,0,0,0900006480b6a6db
FDA-2010-N-0381-0006,FDA,FDA-2010-N-0381,"Margaret Hamburg, M.D., Commissioner of Food and Drugs, Generic Drug User Fee; Public Meeting, September 17, 2010 - Presentation",Other,TS-Testimony,2010-10-07T04:00:00Z,2010,10,2010-10-07T04:00:00Z,,2013-07-27T23:34:04Z,,0,0,0900006480b6a6d3
FDA-2010-N-0381-0008,FDA,FDA-2010-N-0381,"Helen N. Winkle, Director, Office of Pharmaceutical Science, CDER, Generic Drug User Fee; Public Meeting, September 17, 2010 - Presentation",Other,TS-Testimony,2010-10-07T04:00:00Z,2010,10,2010-10-07T04:00:00Z,,2013-08-11T03:11:09Z,,0,0,0900006480b6a6d5
FDA-2010-N-0381-0020,FDA,FDA-2010-N-0381,"Mylan Pharmaceuticals (Heather Bresch), Generic Drug User Fee; Public Meeting, September 17, 2010 - Presentation",Other,TS-Testimony,2010-10-07T04:00:00Z,2010,10,2010-10-07T04:00:00Z,,2013-07-27T23:34:06Z,,0,0,0900006480b6a735
FDA-2010-N-0381-0012,FDA,FDA-2010-N-0381,"Judy Cahill, Academy of Managed Care Pharmacy, Generic Drug User Fee; Public Meeting, September 17, 2010 - Presentation",Other,TS-Testimony,2010-10-07T04:00:00Z,2010,10,2010-10-07T04:00:00Z,,2013-07-27T23:34:05Z,,0,0,0900006480b6a6d9
FDA-2010-N-0381-0010,FDA,FDA-2010-N-0381,"Peter C. Beckerman, J.D. Senior Policy Advisor, FDA Office of Policy, Generic Drug User Fee; Public Meeting, September 17, 2010 - Presentation",Other,TS-Testimony,2010-10-07T04:00:00Z,2010,10,2010-10-07T04:00:00Z,,2013-07-27T23:34:05Z,,0,0,0900006480b6a6d7
FDA-2010-N-0381-0004,FDA,FDA-2010-N-0381,"Generic Drug User Fee; Public Meeting, September 17, 2010 - Agenda",Other,LST-List,2010-10-07T04:00:00Z,2010,10,2010-10-07T04:00:00Z,,2013-07-27T23:34:04Z,,0,0,0900006480b6a501
FDA-2010-N-0381-0001,FDA,FDA-2010-N-0381,Generic Drug User Fee; Public Meeting; Request for Comments,Notice,NM-Notice of Meeting,2010-08-09T04:00:00Z,2010,8,2010-08-09T04:00:00Z,2010-10-18T03:59:59Z,2010-10-07T21:10:45Z,2010-19537,0,0,0900006480b2c0f9